Karl Guenault - IQVIA Holdings Senior Officer
| IQV Stock | USD 216.99 2.24 1.02% |
Executive
Karl Guenault is Senior Officer of IQVIA Holdings
| Address | 2400 Ellis Road, Durham, NC, United States, 27703 |
| Phone | 919 998 2000 |
| Web | https://www.iqvia.com |
IQVIA Holdings Management Efficiency
The company has Return on Asset of 0.0511 % which means that on every $100 spent on assets, it made $0.0511 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.22 %, implying that it generated $0.22 on every 100 dollars invested. IQVIA Holdings' management efficiency ratios could be used to measure how well IQVIA Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IQVIA Holdings' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to climb to 0.06 in 2024, whereas Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, IQVIA Holdings' Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.65 in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.7 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sean Flynn | Vericel Corp Ord | 50 | |
| Dipal Patel | Valneva SE ADR | 49 | |
| Jaime Mercado | Dominari Holdings | N/A | |
| George CPA | Dominari Holdings | 56 | |
| Jennifer Low | 23Andme Holding Co | 55 | |
| Guy Chayoun | 23Andme Holding Co | N/A | |
| Christopher Devall | Dominari Holdings | 41 | |
| Tony Estrada | Denali Therapeutics | N/A | |
| Carole MD | Denali Therapeutics | 51 | |
| David Baker | 23Andme Holding Co | 53 | |
| Christian Taucher | Valneva SE ADR | N/A | |
| Katie Peng | Denali Therapeutics | N/A | |
| Roland DeAngelis | Vericel Corp Ord | N/A | |
| Penny Tom | Equillium | N/A | |
| Jason Keyes | Equillium | 53 | |
| Peter Chin | Denali Therapeutics | N/A | |
| Katie Watson | 23Andme Holding Co | 46 | |
| Jeffrey Stavenhagen | Dianthus Therapeutics | N/A | |
| Rashieda Gluck | Dianthus Therapeutics | N/A | |
| JuanCarlos MD | Valneva SE ADR | 52 | |
| Joshua Drumm | Valneva SE ADR | N/A | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0511 |
IQVIA Holdings Leadership Team
Elected by the shareholders, the IQVIA Holdings' board of directors comprises two types of representatives: IQVIA Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IQVIA. The board's role is to monitor IQVIA Holdings' management team and ensure that shareholders' interests are well served. IQVIA Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IQVIA Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ari Bousbib, Chairman of the Board, President, Chief Executive Officer | ||
| Nicholas Childs, Senior Treasury | ||
| John Danhakl, Independent Director | ||
| Trudy Stein, Chief VP | ||
| Andrea Spannheimer, Global Research | ||
| Richard III, President Solutions | ||
| Walter Staub, President - Research and Development Solutions | ||
| Michael McDonnell, Chief Financial Officer, Executive Vice President | ||
| Andrew Markwick, VP Relations | ||
| Carol Burt, Independent Director | ||
| Jon Resnick, President Canada | ||
| John Leonard, Lead Independent Director | ||
| Keriann Cherofsky, Corporate VP | ||
| Gregg Dearhammer, Safety Sciences | ||
| Cynthia Verst, President Innovation | ||
| Jeffrey MD, Global VP | ||
| James Fasano, Independent Director | ||
| Ronald Bruehlman, Interim Chief Financial Officer, Executive Vice President | ||
| Jeffrey Spaeder, Global VP | ||
| John Connaughton, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Nilton Paletta, President America | ||
| Todd Sisitsky, Independent Director | ||
| Eric Sherbet, Executive Vice President General Counsel, Secretary | ||
| Costa Panagos, President - Research & Development Solutions | ||
| Lucas Glass, Global Excellence | ||
| Rob Kotchie, President Solutions | ||
| Wendy Stewart, President Operations | ||
| Kerri Joseph, SVP Treasury | ||
| Jim Berkshire, Executive Operations | ||
| Alistair Grenfell, Middle Europe | ||
| Karl Guenault, Senior Officer | ||
| Ronald Rittenmeyer, Independent Director | ||
| Brian Mi, President Pacific | ||
| Kevin Knightly, President - Information and Technology Solutions |
IQVIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IQVIA Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0511 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 51.78 B | ||||
| Shares Outstanding | 181.5 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 95.29 % | ||||
| Number Of Shares Shorted | 2.91 M | ||||
| Price To Earning | 103.68 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IQVIA Stock Analysis
When running IQVIA Holdings' price analysis, check to measure IQVIA Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IQVIA Holdings is operating at the current time. Most of IQVIA Holdings' value examination focuses on studying past and present price action to predict the probability of IQVIA Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IQVIA Holdings' price. Additionally, you may evaluate how the addition of IQVIA Holdings to your portfolios can decrease your overall portfolio volatility.